Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | XBP1 | P17861 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 2/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548849 | 0.80 | CTSK (0.34) | TDP1POLBNPSR1MAPTKMT2A | |
| SCHEMBL4217873 | 0.78 | NOS1 (0.33) | KMT2ABTN3A1 | |
| SCHEMBL22711284 | 0.78 | CTSS (0.41) | — | |
| SCHEMBL19560808 | 0.78 | CTSS (0.41) | — | |
| SCHEMBL3617063 | 0.77 | CTSK (0.41) | — | |
| SCHEMBL3617062 | 0.77 | CTSK (0.41) | — | |
| SCHEMBL4745237 | 0.77 | CTSK (0.41) | — | |
| SCHEMBL18104869 | 0.77 | CTSK (0.40) | — | |
| SCHEMBL9691674 | 0.76 | CTSK (0.40) | — | |
| SCHEMBL3545331 | 0.75 | TDP1 (0.40) | TDP1POLBNPSR1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1799653-B1 | Condensed thienopyrimidine derivatives for the treatment of cancer | BAYER IP GMBH (DE) | 2013-03-20 | — | — | EP | disclosed |
| US-8207172-B2 | Pyrimidinothienoindazoles useful for the treatment of hyperproliferative disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20110172224-A1 | NOVEL HETEROCYCLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-03-03 | — | — | US | disclosed |
| EP-1819711-B1 | PYRIMIDOTHIENOINDAZOLES CAPABLE OF INHIBITING TYROSINE KINASES OF THE EPIDERMAL GROWTH FACTOR | BAYER SCHERING PHARMA AG (DE) | 2010-04-21 | — | — | EP | disclosed |
| US-20090186887-A1 | NOVEL PYRIMIDOTHIENOINDAZOLES | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-7511048-B2 | Pyrimidothienoindazoles | BAYER PHARMACEUTICALS CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | BAYER PHAMACEUTICALS CORPORATION (US) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070299066-A1 | Novel Pyrimidothienoindazoles | CCNI, TPMT, TYMP | TDP1 1002/4885POLB 213/4885NPSR1 4512/4885 |
| US-20110053928-A1 | PYRIMIDOTHIENOINDAZOLES | CCNI, TPMT, TYMP | TDP1 524/4885POLB 140/4885NPSR1 4293/4885 |
| US-20110172224-A1 | NOVEL HETEROCYCLES | CCNI, PCNA, CCNA1 | TDP1 1477/4885POLB 277/4885NPSR1 3764/4885 |
| US-20090186887-A1 | NOVEL PYRIMIDOTHIENOINDAZOLES | CCNI, TPMT, TYMP | TDP1 1002/4885POLB 213/4885NPSR1 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.